Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines Immunotherapy
Data on cancer vaccines immunotherapy detailed by researchers at Kapodistrian University, Cancer Immunology and Immunotherapy Center
July 22nd, 2008
New research, 'Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties,' is the subject of a report. According to recent research from Athens, Greece, "HER-2/neu oncoprotein is overexpressed in a variety of human tumors and is associated with aggressive disease. Immunogenic HER-2/neu CTL epitopes have been used as vaccines for the treatment of HER-2/neu positive malignancies with limited success." "By applying prediction algorithms for MHC class I ligands and proteosomal cleavages, in this study, we describe the identification of HER-2/neu decamer LIAHNQVRQV spanning residues 85-94 (HER-2(10(85))). HER-2(10(85))...
Source: Cancer Weekly (2008-07-22)
|
